KRAS G12C Peptide (VVVGACGVGK)
Antibody screening, T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, Cellular immune response
Showing 177–192 of 281 results
-
-
KRAS G12D Peptide (GADGVGKSAL)
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research
-
-
KRAS G12D Peptide (VVVGADGVGK)
Antibody screening, T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, Cellular immune response
-
KRAS G12V Peptide (VVGAVGVGK)
Antibody screening, T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, Cellular immune response
-
KRAS G12V Peptide (VVVGAVGVGK)
Antibody screening, T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, Cellular immune response
-
KRAS WT Peptide (VVVGAGGVGK)
Antibody screening, T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, Cellular immune response
-
-
LCMV gp33–41
This is the H-2Db restricted epitope derived from the lymphocytic choreomeningitis virus (LCMV) glycoprotein gp 33; residues 33 to 41.
-
-
LL-37, scrambled
The cathelicidin anti-microbial peptide LL-37 corresponds to aa 134-170 of the human cationic antimicrobial protein 18 (hCAP18). This peptide is the scrambled version.
-
LL37 (Human)
The cathelicidin anti-microbial peptide LL-37 is involved in the reepithelialization of human skin wounds and is lacking in chronic ulcer epithelium. LL-37(human) is a cathelicidin-derived peptide with antimicrobial and angiogenic activity.
-
LMP2 Peptide (SSCSSCPLTK)
LMP2 peptide, is a crucial component of the immunoproteasome, which plays a significant role in antigen processing and presentation.
-
-
MAGE-3 (161-169)
Antigenic peptide EVDPIGHLY encoded by MAGE-3 and known to be presented by HLA-A*0101 is currently being used in therapeutic vaccination trials.
-
MAGE-A3 (195-203)
This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.